COLGATE PALMOLIVE CO (CL)

Insider Trading Filed: 2026-05-13

Key Insights

Director Brian Newman received 2,075 shares of common stock as an annual director grant at $0.00 (compensation, not market purchase), indicating routine director compensation activity rather than voluntary market purchases.
Newman also received 2,424 stock options with an exercise price of $86.74, vesting in equal annual installments over three years starting May 11, 2027, showing alignment with company long-term performance.
Newman's total beneficial ownership stands at 7,621 shares directly owned plus 36 shares held indirectly through a family trust, representing a modest director-level stake with no significant concentration.
This is a routine annual director compensation grant filed within standard timeframes, with no evidence of material insider trading activity or concerning patterns that would signal management confidence or concern about company valuation.

Current Report Filed: 2026-05-13

Key Insights

All 10 director nominees were successfully elected with strong support, with Christopher S. Boerner receiving the highest approval at 99.1% of votes cast, indicating solid shareholder confidence in board composition and governance.
PricewaterhouseCoopers LLP was ratified as the independent auditor with 92.3% shareholder approval, demonstrating continued confidence in the company's financial oversight and audit practices.
Executive compensation received advisory approval with 93.2% support, suggesting shareholders are aligned with management's pay structure and incentive arrangements.
Two activist-backed stockholder proposals were decisively rejected: the DEI-related proposal received only 2.2% support and the independent board chairman proposal received only 28.8% support, indicating the current board structure and leadership approach have strong shareholder backing.

Insider Trading Filed: 2026-05-13

Key Insights

Director John P. Bilbrey received 2,075 shares as an annual director stock grant with $0 exercise price, indicating routine compensation through equity rather than market purchases.
Grant of 2,424 stock options at $86.74 exercise price with 3-year vesting schedule beginning May 2027 represents standard annual director incentive compensation aligned with shareholder interests.
Bilbrey maintains total beneficial ownership of 39,820 direct shares plus 4,719 indirect shares (held in trust), demonstrating meaningful personal stake in company performance.
The transaction occurs through the company's incentive compensation plan rather than open market activity, suggesting no meaningful signal about management's near-term outlook on stock valuation.

Insider Trading Filed: 2026-05-13

Key Insights

Director Christopher S. Boerner received 1,383 shares of common stock as an annual director grant on 05/11/2026, indicating routine compensation practices aligned with incentive plan governance.
Boerner also received 2,020 stock options with an exercise price of $86.74, vesting in equal annual installments over three years starting May 2027, representing standard equity incentive alignment with shareholder interests.
The transaction was executed at $0.0000 price for the stock grant, confirming this was a non-compensatory award rather than an open market purchase, consistent with director compensation programs.

Insider Trading Filed: 2026-05-13

Key Insights

Director John T. Cahill acquired 2,075 shares of common stock on 05/11/2026 as part of an annual director stock grant with a $0.0000 price, indicating this was a compensation grant rather than a market purchase.
Cahill received 2,424 stock options with an exercise price of $86.74, vesting in equal annual installments over three years starting May 11, 2027, demonstrating the company's standard director incentive compensation structure.
Following these transactions, Cahill's direct beneficial ownership increased to 28,216 shares, with an additional 36,357 shares held indirectly through a trust, showing meaningful cumulative stake in the company.
The routine nature of these grants (annual director compensation) combined with standard vesting schedules suggests no material insider concerns about company performance or valuation.

Insider Trading Filed: 2026-05-13

Key Insights

Director Lisa Edwards acquired 2,075 shares of common stock on 05/11/2026 through an annual director stock grant, increasing her direct beneficial ownership to 18,182 shares, indicating routine annual compensation.
Edwards received 2,424 stock options with a strike price of $86.74, vesting in equal annual installments over three years starting May 2027, representing standard director equity incentive compensation.
The transaction reflects normal periodic director compensation under Colgate's incentive compensation plan rather than a significant insider trading signal, as both the stock grant and option award are described as annual director grants.

Insider Trading Filed: 2026-05-13

Key Insights

Director Harris C Martin received 1,556 shares of common stock as part of an annual director stock grant with zero exercise price, indicating standard compensation practice rather than market-based acquisition.
Martin was granted 2,424 stock options at $86.74 exercise price vesting over three years beginning May 2027, representing confidence in the company's future valuation at that strike level.
Post-transaction beneficial ownership increased to 24,517 shares held directly, demonstrating the director's continued investment in the company alongside his board service obligations.

Insider Trading Filed: 2026-05-13

Key Insights

Director Lorrie M. Norrington acquired 2,075 shares of common stock at no cost ($0.0000 price) on 05/11/2026, representing a routine annual director stock grant under the company's incentive compensation plan, now holding 42,312 shares directly.
Norrington received 2,424 stock options with an exercise price of $86.74, vesting in equal annual installments over three years beginning May 11, 2027, indicating standard director compensation practices aligned with long-term incentive structures.
The filing shows routine annual director compensation grants rather than discretionary insider buying or selling, which provides limited insight into management's confidence or concerns about the company's future stock performance.

Insider Trading Filed: 2026-05-13

Key Insights

Director Martina Hundmejean received 2,075 shares of common stock as an annual director grant valued at $0 (likely a restricted stock unit grant), increasing her direct beneficial ownership to 16,206 shares.
Director received 2,424 stock options with an exercise price of $86.74, vesting in equal annual installments over three years starting May 11, 2027, demonstrating standard director compensation practices.
The filing indicates routine annual director equity compensation rather than open market transactions, with no evidence of significant insider buying or selling that would signal confidence or concern about the stock's valuation.

Insider Trading Filed: 2026-05-13

Key Insights

Director Nelson Kimberly A acquired 2,075 shares of common stock on 05/11/2026 at $0.00, indicating a non-cash compensation grant rather than open market purchase, which is routine for annual director equity awards.
The director's total beneficial ownership across direct and indirect holdings reaches approximately 12,639 shares (11,634 direct + 575 family trust + 215 spouse + 1,799 trust), demonstrating significant personal alignment with shareholder interests.
Concurrent with the stock grant, the director received 2,424 stock options with a $86.74 exercise price vesting over three years, representing the standard annual director compensation package under the company's incentive plan.
This filing reflects routine annual director compensation grants with no indication of material insider trading activity, insider selling, or changes in shareholding strategy.

Insider Trading Filed: 2026-05-11

Key Insights

Chief People Officer Sally Massey sold 8,599 shares on 05/07/2026 at a weighted average price of $87.41, representing a significant insider sale by a senior executive.
The sale was executed across multiple transactions with prices ranging from $87.36 to $87.53, suggesting a deliberate distribution rather than a single transaction.
Massey retains direct beneficial ownership of 13,785 shares plus 8,152 shares indirectly held through the company's 401(k) plan, indicating she maintains a material stake in the company despite the sale.
The transaction occurred during a period when executive officers typically have restricted trading windows, suggesting this sale may have been pre-planned under a Rule 10b5-1 trading plan for compliance.

Quarterly Report Filed: 2026-05-01

Key Insights

Strategic Growth and Productivity Program is actively underway with documented minimum and maximum estimates across all geographic segments and business units, indicating comprehensive operational restructuring efforts throughout 2026.
The filing shows multiple debt instruments outstanding (Notes due 2029, 2034, 2035, and 2039) with varying rates, suggesting a layered debt maturity structure that management is actively managing.
CareTop Co Pty Ltd acquisition was completed in April 2025, representing a strategic expansion move that warrants monitoring for integration progress and contribution to earnings in subsequent quarters.
The presence of extensive contingent liability disclosures related to lawsuits and asset-related costs suggests Colgate is managing significant operational and legal complexities that could impact future financial results.

Current Report Filed: 2026-05-01

Key Insights

Colgate-Palmolive expanded its Strategic Growth and Productivity Program with cumulative pre-tax charges now estimated at $350-550 million (up from $200-300 million), indicating significant restructuring scope but also confidence in long-term strategic positioning aligned with 2030 goals.
The program's cost structure shows 70-80% employee-related expenses with 80-90% resulting in cash expenditures, representing substantial near-term cash outflows primarily through 2028, though the company appears to anticipate efficiency gains that justify the investment.
Geographic allocation reveals the heaviest restructuring burden on EMEA (25-30%) and Corporate (20-25%), suggesting operational consolidation in overhead-heavy regions, while Asia Pacific receives lighter adjustment (10-15%), potentially reflecting stronger growth markets.
Q1 2026 earnings were announced alongside this expansion, but the filing provides no earnings surprises or financial performance details, limiting visibility on whether operational results justify the increased restructuring commitment.

Current Report Filed: 2026-04-09

Key Insights

Colgate-Palmolive has announced the retirement of its Chief Legal Officer and Secretary, Jennifer M. Daniels, and the appointment of Betsy Fishbone as the new Chief Legal Officer and Secretary effective June 1, 2026, indicating a transition in the company's leadership.
The company has also elected Jennifer M. Daniels to the position of Vice Chair, which suggests a planned transition and continuity in the company's operations.
The 8-K filing does not mention any material agreements, earnings surprises, or other significant events, indicating this is a routine organizational change.

Insider Trading Filed: 2026-04-03

Key Insights

Insider Lorrie M. Norrington, a director of Colgate-Palmolive, has acquired 294 shares of the company's common stock at $89.05 per share, increasing her direct beneficial ownership to 40,160 shares.
This purchase suggests Norrington's confidence in Colgate-Palmolive's future performance and aligns her interests with those of shareholders.
The timing of the transaction, occurring in early April 2026, may indicate Norrington's positive outlook on the company's upcoming quarterly or annual results.

Insider Trading Filed: 2026-04-03

Key Insights

Insider Brian Newman acquired 210 shares of Colgate-Palmolive stock, increasing his direct ownership to 5,534 shares.
Newman also owns an additional 36 shares indirectly through a family trust, indicating his alignment with the company's long-term success.
The purchase price of $89.05 per share suggests Newman views the stock as undervalued and has confidence in Colgate-Palmolive's future performance.

Insider Trading Filed: 2026-04-03

Key Insights

John P. Bilbrey, a director of Colgate-Palmolive, acquired 266 shares of the company's common stock at $89.05 per share, increasing his direct ownership to 37,665 shares.
Bilbrey also has an indirect ownership of 4,719 shares held in a trust, indicating his commitment to the company.
The transaction appears to be a routine deferral of a portion of Bilbrey's annual cash retainer into a stock unit account, which is a common practice for non-employee directors.

Current Report Filed: 2026-03-17

Key Insights

Colgate-Palmolive has realigned its reportable operating segments by combining its Europe and Africa/Eurasia (excluding Russia and Belarus) segments, as well as its Skin Health business, into a new Europe, Middle East and Africa segment. This change is part of the company's Strategic Growth and Productivity Program to optimize operations and drive growth.
Russia and Belarus, previously reported in the Africa/Eurasia segment, will now be part of the Asia Pacific segment. This realignment does not impact the company's historical consolidated results, financial position, or cash flows.
To provide investors with historical information on the new reporting structure, Colgate-Palmolive has recasted its segment information for the past three years and included it as an exhibit to the 8-K filing.

Current Report Filed: 2026-03-12

Key Insights

Colgate-Palmolive appointed Christopher S. Boerner, Ph.D., the CEO and Board Chair of Bristol-Myers Squibb, to its Board of Directors, adding significant pharmaceutical and healthcare expertise to the company's leadership.
Steven A. Cahillane, a current Colgate-Palmolive director, announced he will not stand for re-election to the Board due to the demands of his new role as CEO of The Kraft Heinz Company.
Colgate-Palmolive is diversifying its Board composition by bringing in an experienced executive from the pharmaceutical industry, which could help the company explore new growth opportunities in adjacent markets.

Insider Trading Filed: 2026-02-25

Key Insights

John Hazlin, the Chief Growth Officer, acquired 12,803 shares of Colgate-Palmolive through vesting of performance-based restricted stock units (PBRSUs), indicating the company's confidence in his leadership.
Hazlin also disposed of 6,117 shares to cover tax liabilities, suggesting he maintains a significant direct ownership stake in the company.
The transaction is part of the company's incentive compensation plan, aligning the executive's interests with shareholders.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information